(Q37299387)

19 August 2017

1 reference

title

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases (English)

1 reference

19 August 2017

0 references

Justin M Ko

1

1 reference

19 August 2017

Alice B Gottlieb

series ordinal

2

1 reference

19 August 2017

Joseph F Kerbleski

series ordinal

3

1 reference

19 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Journal of Dermatological Treatment

19 August 2017

published in

1 reference

19 August 2017

volume

20

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

100-108

1 reference

Epidemiology and estimated population burden of selected autoimmune diseases in the United States

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Role of biological agents in immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Newer therapeutic approaches: spondyloarthritis and uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Development of new-onset psoriasis while on anti-TNFalpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Pustular skin lesions in patients treated with infliximab: report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Psoriasiform eruption induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Psoriasis after treatment of juvenile idiopathic arthritis with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Skin reaction to adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Increased Sensitivity to Interferon-α in Psoriatic T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Tumor necrosis factor biology in experimental and clinical arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630802441234

10.1080/09546630802441234

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference